vival found with increasing CD4 + cell levels. Patients were also divided into groups with high (n = 26) and low (n = 27) levels of CD3 + using median expression as a cutoff. Median survival was 20.5 and 18.8 months, respectively, and the 5-year survival estimate was 18.0 months (95% CI, 6.0-35.1 months) and 5.56 months (95% CI, 0.5-2.6 months), respectively. A similar analysis was performed for those with high (n = 22) and low (n = 22) levels of postoperative circulating monocytes. Median survival was 25.3 and 21.6 months, respectively; 5-year estimate of survival, 21.3 months (95% CI, 4.7-45.9 months) and 9.5 months (95% CI, 0.9-31.1 months), respectively.
No takes yet. Share an insight, caveat, or question.
Dubina et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: